MinorAntiplatelet agents (low dose) / NSAIDs (analgesic dose)×Other antidepressants (NaSSA)
Updated · Methodology
Mechanism
Acetylsalicylic acid strongly and irreversibly inhibits platelet aggregation for several days. In the body, it is converted to salicylic acid, which is metabolised mainly in the liver, and the kidneys excrete the metabolites (acetylsalicylic acid SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The antidepressant mirtazapine blocks central presynaptic alpha-2 receptors and so increases noradrenergic and serotonergic transmission. In vitro data from human liver microsomes show that CYP2D6, CYP1A2 and CYP3A4 take part in its metabolism (mirtazapine SmPC, AEMPS). The acetylsalicylic acid documents advise avoiding, whenever possible, drugs that may increase the risk of bleeding. Their examples are corticosteroids, non-steroidal anti-inflammatory drugs, selective serotonin reuptake inhibitors (SSRIs), antiplatelet drugs and anticoagulants (acetylsalicylic acid SmPC, AEMPS). Mirtazapine is not on that list, and its documents neither class it as an SSRI nor mention bleeding in their warnings (mirtazapine SmPC, AEMPS; mirtazapine label, US Food and Drug Administration, FDA). The documents say nothing about either drug changing the levels of the other.
Symptoms
The documents describe no symptoms linked to this combination. Treatment with non-steroidal anti-inflammatory drugs, which include acetylsalicylic acid, is associated with bleeding, ulceration and perforation of the upper gastrointestinal tract. These can occur at any time during treatment without previous symptoms (acetylsalicylic acid SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Dyspepsia, abdominal pain, nosebleeds and bleeding from the gastrointestinal and urogenital tracts are common (acetylsalicylic acid SmPC, AEMPS). With mirtazapine, more than 5% of patients have somnolence, sedation, dry mouth, increased appetite and weight gain, dizziness and fatigue (mirtazapine SmPC, AEMPS).
Management
According to the documents, the combination is acceptable, and the doses of acetylsalicylic acid and mirtazapine need no change. No document names the pair. Mirtazapine is not among the drugs to be avoided whenever possible with acetylsalicylic acid because of the bleeding risk (acetylsalicylic acid SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). It is not among the US label's examples of drugs that increase the bleeding risk either (aspirin label, US Food and Drug Administration, FDA). The UK National Institute for Health and Care Excellence (NICE) guideline on depression in adults with a chronic physical health problem suggests considering mirtazapine for people taking acetylsalicylic acid (NICE CG91). Patients are warned about the bleeding risk and its signs: black stools, vomiting blood and marked weakness. If bleeding, ulceration or perforation occurs, acetylsalicylic acid is stopped at once (acetylsalicylic acid SmPC, AEMPS). Alcohol taken with acetylsalicylic acid increases the risk of gastrointestinal bleeding (acetylsalicylic acid SmPC, AEMPS). Alcohol is avoided during treatment with mirtazapine (mirtazapine SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Remeron/RemeronSolTab (mirtazapine) prescribing information (2025)– FDA, DailyMed, Remeron/RemeronSolTab, Organon LLC, setid 98ad1917-a094-44f5-a28f-a64a8cfcd887, revisión 08/2025, secciones 4, 5.3, 5.8, 7 y 12.3
- AEMPS: Ficha técnica de Rexer Flas 15 mg comprimidos bucodispersables (mirtazapina) (2021)– AEMPS, CIMA, nº registro 64819, revisión 04/2021, secciones 4.3, 4.5 y 5.1
- FDA: Durlaza (aspirin) prescribing information (2015)– FDA, DailyMed setid 4c2a1403-3862-1efd-0a91-444989222b37 (New Haven Pharmaceuticals), revised 09/2015, sections 7
- AEMPS: Ficha técnica: Ácido acetilsalicílico, Adiro 100 mg (nº registro 62825) (2026)– AEMPS, CIMA, nº registro 62825 (Adiro 100 mg comprimidos gastrorresistentes EFG), revisión 07/2026, secciones 4.3, 4.4 y 4.5
- NICE: Depression in adults with a chronic physical health problem: recognition and management (CG91) (2009)– NICE clinical guideline CG91, published 28.10.2009, recommendations 1.5.2.6, 1.5.2.9 and 1.5.2.11 (interactions of SSRIs with other medication)